San Diego’s Biocept Inc. struck a deal with Quest Diagnostics Inc. that will expand the use of Biocept’s tests into Mexico.

Under the terms of the agreement, New Jersey-based Quest will perform Biocept’s blood test for lung cancer in that country. Financial and other terms of the agreement were not disclosed.

"Our ability to expand internationally is a testament to the scalability of our platform as we deliver liquid biopsy testing to the medical community worldwide," Biocept President and CEO Michael Nall said in a statement.

Biocept offers liquid biopsies for lung, breast, gastric, colorectal, prostate, and skin cancers. Its technology platform, called Target Selector, captures and analyzes both cellular and cell-free circulating tumor DNA, to find mutations associated with those cancers.

"Detecting the EGFR mutation can qualify patients for targeted therapy treatments that could lead to better outcomes," said Biocept’s VP of commercial operations Raaj Trivedi.

The deal is the latest international agreement for Biocept. Last month, the firm signed a marketing and distribution agreement for Israel with Tel Aviv-based Progenetics.